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Abstract. In genetic epidemiological studies, family history data are collected on relatives of
study participants and used to estimate the age-specific risk of disease for individuals who carry a
causal mutation. However, a family member’s genotype data may not be collected due to the high
cost of in-person interview to obtain blood sample or death of a relative. Previously, efficient non-
parametric genotype-specific risk estimation in censored mixture data has been proposed without
considering covariates. With multiple predictive risk factors available, risk estimation requires a
multivariate model to account for additional covariates that may affect disease risk simultaneously.
Therefore, it is important to consider the role of covariates in the genotype-specific distribution
estimation using family history data. We propose an estimation method that permits more precise
risk prediction by controlling for individual characteristics and incorporating interaction effects with
missing genotypes in relatives, and thus gene-gene interactions and gene-environment interactions
can be handled within the framework of a single model. We examine performance of the proposed
methods by simulations and apply them to estimate the age-specific cumulative risk of Parkinson’s
disease (PD) in carriers of LRRK2 G2019S mutation using first-degree relatives who are at genetic
risk for PD. The utility of estimated carrier risk is demonstrated through designing a future clinical
trial under various assumptions. Such sample size estimation is seen in the Huntington’s disease
literature using the length of abnormal expansion of a CAG repeat in the HTT gene, but is less
common in the PD literature.
Keywords: Mixture distribution; Censored data; Parkinson’s disease; Penetrance function; Disease
risk estimation.
1. Introduction
Estimating the cumulative risk of disease onset by a certain age for individuals who carry a
causal mutation (i.e., age-specific penetrance function), has important implications for both ge-
netic counseling and clinical trial planning. For example, the age-specific penetrance function will
provide prognostic information for patients who are at risk of a genetic disorder wishing to know the
significance of their biological features in relation to their risk of disease-onset. This will ultimately
allow genetic counselors to interpret risk of disease according to each individual’s unique biological
characteristics and help patients make important decisions regarding genetic testing. Furthermore,
cumulative disease risk obtained from an untreated population provides an estimate of the baseline
event rate when powering a clinical trial recruiting individuals at genetic risk. A lack of treatment
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options for changing the trajectory of Parkinson’s disease (PD) or Alzheimer’s disease (AD) pro-
gression, in combination with an increasing elderly population, poses a rising economic burden on
patients and the healthcare system [1], which makes developing innovative new treatments that
delay disease onset an urgent research priority [1, 2]. In many genetic epidemiological studies of
these late-onset disorders, family history data on probands at genetic risk are collected and used to
estimate the penetrance [3, 4, 5, 6]. In a typical study, affected individuals (e.g., Ashkenazi Jewish
(AJ) PD patients) including carriers and non-carriers are recruited, and report family history of
disease, including age at onset of the disease, in their first-degree relatives. However, genotype
information in many relatives may not be available due to death of a relative (e.g., parents of a
proband) or lack of resources to collect blood samples in all family members [5, 7, 8]. This practical
difficulty is frequently encountered in cases of late onset disease (e.g., PD or AD) when parents are
often deceased. When some genotype information is missing, the probability of a family member
carrying a mutation is estimated based on the mutation status in the initial cohort of subjects (e.g.,
probands) and the relative’s relationship to the proband under Mendelian transmission. [3, 5, 8].
With missing genotypes and ages of disease onset subject to right censoring, the observed data
consists of censored mixture data. Previously, a sieve maximum likelihood nonparametric method
for such data was proposed to estimate distribution function in carriers and non-carriers [9]. The
method was applied to a recent study [5] to estimate age-specific risk of PD in LRRK2 gene mutation
carriers compared to non-carriers. To evaluate the sex effect on the carrier risk in this study,
stratified analyses were carried out and the penetrance function was estimated in a subpopulation
of male and female relatives separately [5]. Stratified analysis maintains the nonparametric nature
in the sense that it does not assume any specific model of the association between the covariates
and the outcome. However, a limitation is reduced efficiency; when multiple covariates are available
that may affect the penetrance simultaneously, stratifying by a larger number of covariates reduces
the sample size and estimation may become infeasible. Therefore, when considering the role of
other demographic covariates or environmental risk factors on modifying the penetrance functions,
it is desirable to link covariates to the penetrance function through appropriate semiparametric
regression models.
Another advantage of introducing covariates to the model is that gene by gene interaction or
gene by environmental risk factor interaction can be handled within the framework of a single
model. A better characterization of the interactions between genetic and environmental factors
helps to understand the pathogenesis of multifactorial diseases [10]. However, if the gene itself is
examined without considering its potential interactions with other factors, the effect of the genetic
factors on complex mechanism might be missed [11]. For example for PD, variants in LRRK2 and
PARK16 genetically interact to increase the risk of PD. A recent study shows that LRRK2 interacts
with RAB7L1 to modify PD risk [12, 13]. Therefore, it is of interest to consider genotype-specific
risk estimation in the presence of their interaction with other genetic or environmental factors. A
LRRK2 by gender interaction was suggested in a prior stratified analysis in our motivating study
[5]. It is desirable to test for this interaction in a parsimonious model. One challenge in testing for
gene by other risk factor interaction in [5] and other similar studies [4] is that genotypes are not
available in most first-degree relatives.
In this paper, we propose a covariate-adjusted semi-parametric estimation method that permits
including multiple covariates and interaction effects in the presence of missing genotypes through
a semiparametric regression model. Compared to previous nonparametric approaches, our method
allows controlling for individual characteristics such as sex, ethnicity, environmental risk factors,
and genotypes at other loci. Moreover, gene-gene interactions and gene-environment interactions
can also be handled within the framework of a semiparametric model. Thus, we extend the prior
work [9] on a single gene to handle multiple genes. The analyses may provide insights on whether
demographics or environmental variables play a role in modifying the penetrance. In addition,
to assist with clinical trial planning, we estimate cumulative risk distribution of disease onset in
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the overall sample by marginalizing over covariate distributions using estimates obtained from the
conditional model given covariates. Sample size estimation has been calculated in the Huntington’s
disease literature due to the known disease causal gene and its near complete the penetrance.
However, using estimated mutation risk to design a clinical trial for PD is less common due to
reduced penetrance. Our estimate of LRRK2 penetrance in the AJ population provides a unique
opportunity to power a future clinical trial in this population with a higher PD risk. When external
or prior information on the covariate distribution in the target trial population is available, they can
be easily incorporated. The performance of the proposed method is examined through extensive
simulation studies. Finally, we apply the proposed approach to estimate the age-specific risk of PD
for first-degree relatives with LRRK2 mutations [4, 14, 15] and test for interaction between LRRK2
mutation and other covariates.
2. Methods
2.1. Notation and likelihood function. Let Ti be the age-at-onset of a disease which is subject
to random censoring given covariates. Let Xi indicate the carrier status at the causal gene of
interest, with one indicating the carrier group (each individual has at least one copy of the mutation)
and zero indicating the non-carrier group under an autosomal dominant inheritance model. Note
that LRRK2 G2019s mutation has an autosomal dominant mode of inheritance [5]. Thus, here we
rely on biological knowledge and in the following consider a dominant model. It is straightforward
to extend to other genetic models (recessive or additive). Let Zi and W i be a vector of auxiliary
covariates collected on the probands and relatives, respectively. For example, Zi may include
demographic information on probands in each family representing family-specific covariates to be
adjusted, and W i may include relatives’ own individual-specific characteristics. Due to potential
right-censoring of the age-at-onset information and unknown Xi, the observed data from n subjects
consist of {Yi = Ti
∧
Ci,∆i = I(Ti 6 Ci),Zi,W i}, i = 1, . . . , n, where Ci denotes the censoring
time assumed to be conditionally independent of Ti given Zi and W i.
In our motivating study, the sampling design was to first recruit probands (either affected by
the disease or control) in a three-site PD consortium studying LRRK2 G2019S [5, 9]. All the
probands are genotyped and their phenotype information and covariates were collected (Zi and Yi
are known). Next, the family history of the disease and some demographic information of the first-
degree relatives, were collected through a systematic interview with the probands or the relatives
themselves [7] (Ti and W i are known). Genotypes on most relatives were not available (Xi can be
missing). Even though in some cases the relatives’ genotypes are unknown, one can estimate the
probability of a relative being a carrier, i.e., P (Xi = 1). For example, LRRK2 gene mutation is
associated with autosomal dominant PD [16] and knowing just one parent is homozygous carrier will
lead to infer the child is a carrier with probability one. Moreover, a child of a heterozygote carrier
parent has a probability of 0.5 of carrying this mutation under the Mendelian transmission and a low
mutation prevalence (approximately zero). If the mutation prevalence in the general population is
known and denoted by c, then the probability of this child being a carrier is P (Xi = 1) = 0.5(1+c).
To present the likelihood function, we denote a finite number of possible values for P (Xi) in a study
as {p1, ..., pm}, and let an indicator variable, Gi, represent m distinct carrier probabilities, where
Gi = g indicates P (Xi = 1) = pg, g = 1, . . . ,m. The observed genotypes in relatives can be
incorporated by letting pg equal one for carriers and zero for non-carriers. The model identifiability
conditions on pg were examined in Lemma 1 of [9].
Because the mutation status Xi may be unknown, the observed conditional likelihood takes a
mixture form as
n∏
i=1
m∏
g=1
{
[pgf1(Yi;Zi,W i) + (1− pg)f0(Yi;Zi,W i)]∆i
×[1− pgF1(Yi;Zi,W i)− (1− pg)F0(Yi;Zi,W i))]1−∆i
}I(Gi=g)
,
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where fk(y; z,w) is the conditional probability density function of T in the group with X = k
given covariates Z = z and W = w, and Fk(y; z,w) is the corresponding cumulative distribution
function. Compared to the prior work [9], the main contribution here is to accommodate covariates,
gene by environmental risk factor interaction, and potential gene by gene interaction, through
regression models. Thus, consider the hazard model allowing for the interaction between Xi and
W i as
λ(t|Xi,W i,Zi) = λ0(t) exp{β(t)Xi + ηTW i + θTW iXi + γTZi}.(1)
Note that we allow the hazard ratio between two genotype groups to be time-dependent (i.e., β(t)
is time-varying) to accommodate the potential time-varying mutation effect and protect against
misspecification of the penetrance function. To adjust for W i, Zi and interaction effect in a
parsimonious way, their effects are assumed to be time-invariant. It is possible to extend to time-
varying case. The observed data likelihood is
n∏
i=1
m∏
g=1
{[
pgλ0(Yi)e
β(Yi)+(η+θ)
TW i+γ
TZi exp
{
−
∫ Yi
0
eβ(t)+(η+θ)
TW i+γ
TZidΛ0(t)
}
+ (1− pg)λ0(Yi)eηTW i+γTZi exp{−Λ0(Yi)eηTW i+γTZi}
]∆i
×
[
pg exp
{
−
∫ Yi
0
eβ(t)+(η+θ)
TW i+γ
TZidΛ0(t)
}
+ (1− pg) exp{−Λ0(Yi)eηTW i+γTZi}
]1−∆i}I(Gi=g)
.(2)
We can further expand the model to accommodate penetrance estimation for more than one
gene. For example, in our motivating LRRK2 consortium study, probands were genotyped for the
LRRK2 G2019S and glucocerebrosidase (GBA) mutations, but the probands who carried GBA
mutation were excluded [5] in prior analyses to investigate the LRRK2 G2019S mutation effect on
the PD-onset that is not due to the other genetic factors. We can now further estimate the risk
of PD accounting for multiple genotypes such as cumulative risk for those carrying both LRRK2
and GBA mutation. Let Ui denote the potentially unobserved GBA carrier status. The hazard
function corresponding to two genes is expanded as
λ(t|Xi, Ui,W i,Zi) = λ0(t) exp{β1(t)Xi + β2(t)Ui + ηTW i + θTW iXi + γTZi},
where βj(t) is the effect of each gene on the disease hazard, respectively. An interaction term
between genes Xi and Ui can also be incorporated when of interest. Because the majority of the
relatives were neither genotyped for LRRK2 nor for GBA, we expand the probability vector of the
carrier status at two loci as P (Xi = g1, Ui = g2) = pg1,g2 . The likelihood function in (2) can be re-
expressed under the expanded hazard model and probability vectors, and the estimation procedure
proceeds as in a single gene case.
2.2. Sieve maximum likelihood estimation with covariates and interactions. To estimate
the parameters Λ0(t) and {β(t),η,θ,γ}, we adapt a hybrid approach involving a nonparametric
estimator and sieve estimation that leads to consistent and semiparametrically efficient estimators
similar to [9]. Specifically, consider using a nonparametric maximum likelihood estimator for Λ0(t)
and a sieve approximation to estimate β(t) by letting β(t) =
∑Kn
j=1 αjφj(t), where φ1(t), . . . , φKn(t)
are basis functions such as B-splines functions. It is computationally intensive and inefficient
to directly maximize (2) over all the parameters, since the log-likelihood is not convex and the
parameters include the potentially large number of jumps of Λ0. However, by treating the mutation
status in all individuals X1, . . . , Xn as missing data, fast numerical computation can be achieved
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by using the expectation-maximization (EM) algorithm [17] due to available closed-form solutions
in the M-step.
The complete data log-likelihood function for (Yi,∆i, Xi, Gi), i = 1, ..., n is given as
n∑
i=1
I(Xi = 1)
∆i log δΛ0(Yi) + ∆i
kn∑
j=1
αjφj(Yi) + ∆i(η + θ)
TW i + ∆iγ
TZi
−
∑
Yk≤Yi
δΛ0(Yk) exp{
kn∑
j=1
αjφj(Yk) + (η + θ)
TW i + γ
TZi}

+
n∑
i=1
I(Xi = 0)
{
∆i log δΛ0(Yi) + ∆iη
TW i + ∆iγ
TZi − Λ0(Yi) exp{ηTW i + γTZi}
}
+
n∑
i=1
m∑
g=1
I(Gi = g,Xi = 1) log pg +
n∑
i=1
m∑
g=1
I(Gi = g,Xi = 0) log(1− pg).
Therefore, in the E-step of EM algorithm, we evaluate the posterior probability of Xi = 1 given
the observation data (Gi, Yi,∆i) as qi = ai/(ai + bi), where
ai = pGi exp{∆i
kn∑
j=1
αjφj(Yi) + ∆i(η + θ)
TW i + ∆iγ
TZi −
∫ Yi
0
e
∑kn
j=1 αjφj(t)+(η+θ)
TW i+γ
TZidΛ0(t)}
bi = (1− pGi) exp{∆iηTW i + ∆iγTZi − Λ0(Yi) exp{ηTW i + γTZi}}.
In the M-step, we maximize
n∑
i=1
qi
∆i log δΛ0(Yi) + ∆i
kn∑
j=1
αjφj(Yi) + ∆i(η + θ)
TW i + ∆iγ
TZi
−
∑
Yk≤Yi
δΛ0(Yk) exp{
kn∑
j=1
αjφj(Yk) + (η + θ)
TW i + γ
TZi}

+
n∑
i=1
(1− qi)
{
∆i log δΛ0(Yi) + ∆iη
TW i + ∆iγ
TZi − Λ0(Yi) exp{ηTW i + γTZi}
}
.(3)
By differentiating (3) with respect to the jump sizes of Λ0(·) at the observed event times, we obtain
close-form solutions
δΛ0(Yi) =
∆i∑n
k=1 I(Yk ≥ Yi)
{
qk exp{
∑kn
j=1 αjφj(Yi) + (η + θ)
TW k + γTZk}+ (1− qk) exp{ηTW k + γTZk}
} .(4)
After substituting (4) into (3) and differentiating with respect to αj , we obtain the score equation
for αj as
n∑
i=1
∆i
qi − ∑nk=1 I(Yk ≥ Yi)qk exp{∑knj=1 αjφj(Yi) + (η + θ)TW k + γTZk}∑n
k=1 I(Yk ≥ Yi)
{
qke
∑kn
j=1 αjφj(Yi)+(η+θ)
TW k+γTZk + (1− qk)eηTW k+γTZk
}
φ(Yi) = 0,
where φ(Yi) = (φ1(Yi), · · · , φkn(Yi))T . The score equations for the other parameters in the M-step
are obtained similarly and the parameters are estimated using Newton-Raphson algorithm. After
obtaining the updated α and {η,θ,γ} values, we use (4) to update the jumps of Λ0(·). We then
iterate between the E-step and M-step till convergence. Note that the baseline hazard function has
a closed-form solution due to the use of nonparametric maximum likelihood estimator, the M-step
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is computationally fast. Asymptotic properties of the baseline cumulative hazard function in a
nonparametric model were studied in Wang et al. (2015) [9], which shows consistency, efficiency,
and convergence to a Gaussian process in the presence of missing genotypes. Similar arguments
(see for example, [18]) can be applied to establish asymptotic properties of estimators considered
here.
To inform planning of a clinical trial, the marginal cumulative risks in carrier and non-carrier
relatives may provide design parameters (e.g., risk of disease in the absence of intervention). Thus,
we can estimate the marginal cumulative distribution of disease age-at-onset in carriers and non-
carriers, respectively, based on the expressions
F1(t) = P (T 6 t|X = 1) = 1−
∫
exp{−Λ0(t)eβ(t)+(η+θ)TW+γTZ}dH(W ,Z|X = 1),
and
F0(t) = P (T 6 t|X = 0) = 1−
∫
exp{−Λ0(t)eηTW+γTZ}dH(W ,Z|X = 0),(5)
where H(W ,Z|X) denotes the conditional probability distribution function of W ,Z given the
mutation carrier status. Since the genotypes X are not observed in some relatives, we estimate
H(W ,Z|X) through an EM algorithm.
3. Simulation Studies
We conducted simulation studies to assess the performance of the proposed method. The simula-
tions were designed to imitate the LRRK2 penetrance study described in Section 4. We generated
survival times similar to the estimated distributions of the actual data in Section 4. The distribu-
tion of the event times for non-carriers in the baseline group (with covariates Zi and W i as zero)
were generated from Weibull(5, 105) and the distributions for carriers and non-carriers in the other
covariate groups were generated under the hazard model (1), allowing for relative’s sex by gene
interaction [9]. The mutation probability pi was taken from {0, 0.02, 0.51, 1}, as in the real data
analysis. 93% of the total sample size n = 2266 were not genotyped and parents, siblings, and
children had a similar rate of available genotypes as in the real example. To evaluate how well our
method works in the case of data sets with a large percentage of censored data points (i.e, data
points where an exact time of age at onset is not known), censoring times were generated from a
uniform distribution to achieve a random choice of censoring rate of 40% or 60%. To ensure valid
inference, we used bootstrap resampling of families to compute the standard errors and construct
confidence intervals for the estimators. The covariates included in the simulation models (sex of
the relative and proband) were fixed at the same values as the real data. We did not include site
of enrollment as a covariate in the simulation model since there was no significant heterogeneity
between sites on the penetrance of PD in the real data analysis.
The goal of the simulation study is to examine the bias and efficiency of estimators. We evaluated
the bias, empirical standard deviation, average of the estimated standard errors, and coverage
probability corresponding to nominal 95% confidence intervals. We set the initial values to be zero
in our simulations and data analysis and we did not find the algorithm to be sensitive to the choice
of initial values. A reasonable way to select the initial values of parameters is to use baseline hazard
ratios estimated from the probands data where all the genotypes are observed. We used exponential
random variables with a mean of one to weight each observation. The simulation results from 1,000
replications with 1,000 bootstrap samples for each simulated data are given in Table 1 and Table
2.
The parameter estimates of the Cox proportional hazards model for the simulation study under
both 40% and 60% censoring rates in Table 1 suggest that estimated hazard ratios (HR) are close
to true HRs with small bias. The empirical variability agrees with the variance estimate based on
the bootstrap and the coverage probabilities are close to the nominal level of 95%. Specifically, the
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estimated HR of predicted carrier male relatives to predicted non-carrier male relatives adjusted for
other covariates was close to the true HR with bias< 0.01 (Estimated HR=1.52, True HR=1.52) and
the estimated standard errors agrees adequately with the empirical standard deviation (SE=0.21,
SD=0.21) with the coverage probability 94%. Moreover, higher HR was estimated for the predicted
carrier female relatives compared to predicted non-carrier female relatives adjusted for other co-
variates which was close to the true HR (Estimated HR=5.20, True HR=4.99) and the estimated
standard errors agrees adequately with the empirical standard deviation (SE=0.80, SD=0.83) with
the coverage probability 93%. Our method performs well even under 60% censoring rate. As
the censoring rate increases from 40% to 60%, we observed the empirical standard deviation and
estimated standard errors increased slightly.
In Table 2, we present the average estimated values of the cumulative distribution functions
(F̂1 for carriers and F̂0 for non-carriers) in male and female relatives at various ages with their
performances. When cumulative risk in male and female relatives were examined separately, the
small bias of estimated penetrance was observed through out the entire range of age (see Table 2
and Figure 1). Specifically, the bias of estimated penetrance to age 80 among predicted mutation
carrier male relative with 40% censoring rate was -0.02% and the estimated standard errors agrees
adequately with the empirical standard deviation (SE=4.19%, SD=4.28%), and the coverage prob-
ability of 93.4% was close to the nominal level. Similar results were observed in female relatives and
our method performs well under both 40% and 60% censoring rates. We note that as the censoring
rate increases, the bias and the variance estimates tend to increase and the coverage probability
tends to decrease. This makes a wider 95% confidence interval for the cumulative risk estimates for
60% censoring rate compared to 40% censoring rate (see Figure 1 and Figure S2). In the Supple-
mentary Material, we observed similar results for the overall penetrance estimates marginalized by
relative’s sex and proband’s sex (see Table S1, Figure S1) as well as for the penetrance estimates
in male and female relatives of male and female probands (see Table S2 and Figure S3 and S4).
Table 1: Summary results for the estimated hazard ratios in the simulation (×10−2) with censoring
rate of 40% or 60%.
Censor Variable Parameter True HR Est HR Bias SD SE CP
40% Carrier status in male β + θ 1.52 1.52 <0.01 0.21 0.21 0.94
Carrier status in female β 4.99 5.20 0.20 0.83 0.80 0.93
Relative’s sex in carriers η + θ 0.73 0.73 <0.01 0.13 0.13 0.93
Relative’s sex in non-carriers η 2.39 2.44 0.05 0.18 0.18 0.93
Carriers · Relative’s sex interaction θ 0.31 0.30 <0.01 0.06 0.06 0.93
Proband’s sex γ 0.71 0.71 <0.01 0.04 0.04 0.95
60% Carrier status in male β + θ 1.52 1.49 -0.03 0.24 0.24 0.96
Carrier status in female β 4.99 4.84 -0.15 0.89 0.94 0.95
Relative’s sex in carriers η + θ 0.73 0.77 0.04 0.16 0.16 0.94
Relative’s sex in non-carriers η 2.39 2.43 0.04 0.22 0.23 0.95
Carriers · Relative’s sex interaction θ 0.31 0.32 0.01 0.08 0.08 0.95
Proband’s sex γ 0.71 0.71 0.01 0.05 0.05 0.94
The Cox proportional hazards model can be written as
λ(t|Carrier statusXi, Relative′s sexi, P roband′s sexi)
= λ0(t) exp{βXi + ηI(Relative′s sexi = Male) + θXiI(Relative′s sexi = Male) + γI(Proband′s sexi = Male).
Denote the true hazard ratio (True HR), estimated hazard ratio (Est HR), average estimation bias over
1,000 replications (Bias), empirical standard deviation (SD), average of estimated standard errors from
bootstraps (SE), and coverage probability corresponding to nominal 95% confidence intervals (CP).
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Table 2: Summary results for the penetrance estimates in male and female relatives marginalized
by proband’s sex in the simulation (×10−2) with censoring rate of 40% or 60%.
Carriers F̂1(·) Non-Carriers F̂0(·)
Censor Relative’s sex Age True Risk Bias SD SE CP True Risk Bias SD SE CP
40% Male 60 16.36 <0.01 1.96 1.96 94.4 11.07 0.05 0.80 0.81 95.9
65 23.37 0.01 2.59 2.57 94.7 16.05 0.09 0.99 0.99 95.2
70 31.95 -0.01 3.22 3.20 94.6 22.36 0.12 1.17 1.18 94.1
75 41.85 -0.04 3.82 3.78 94.1 30.01 0.15 1.38 1.36 94.4
80 52.59 -0.02 4.28 4.19 93.4 38.84 0.24 1.49 1.51 95.9
Female 60 21.71 0.32 2.58 2.55 94.3 4.80 -0.06 0.42 0.42 94.4
65 30.54 0.43 3.29 3.24 94.2 7.07 -0.08 0.57 0.55 93.7
70 40.94 0.50 3.97 3.88 93.9 10.07 -0.12 0.74 0.72 93.0
75 52.34 0.52 4.45 4.36 94.4 13.91 -0.16 0.93 0.91 93.2
80 63.91 0.53 4.69 4.53 93.8 18.67 -0.17 1.12 1.12 94.3
60% Male 60 16.36 -0.14 2.20 2.18 93.5 11.07 0.17 0.84 0.85 95.0
65 23.37 -0.21 2.91 2.88 94.0 16.05 0.23 1.04 1.05 95.2
70 31.95 -0.26 3.63 3.62 94.2 22.36 0.34 1.29 1.27 94.2
75 41.85 -0.51 4.26 4.31 94.7 30.01 0.30 1.48 1.49 94.6
80 52.59 -0.98 4.80 4.83 94.3 38.84 0.06 1.76 1.73 94.1
Female 60 21.71 -0.72 2.79 2.85 94.1 4.80 0.03 0.48 0.48 94.4
65 30.54 -0.99 3.62 3.68 94.2 7.07 0.04 0.65 0.65 94.9
70 40.94 -1.21 4.40 4.50 94.5 10.07 0.07 0.85 0.85 94.6
75 52.34 -1.61 5.02 5.13 94.3 13.91 0.03 1.07 1.08 94.6
80 63.91 -2.14 5.38 5.46 93.2 18.67 -0.13 1.33 1.33 94.1
Denote the true cumulative risk (True Risk), average estimation bias over 1,000 replications (Bias),
empirical standard deviation (SD), average of estimated standard errors from bootstraps (SE), and
coverage probability corresponding to nominal 95% confidence intervals (CP). Results are based on 1,000
simulations with sample size n = 2266.
(a) Male (b) Female
Figure 1: Estimated cumulative risk functions in the simulation with 40% censoring rate: Carriers
(red solid line) and non-carriers (black solid line) in male and female relatives marginalized by
proband’s sex with their 95% confidence intervals (dashed lines) and true cumulative risk functions
(blue solid line).
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4. Application to the AJ Penetrance Study
Since mutations in the LRRK2 gene are identified as a potential cause of autosomal dominant
idiopathic Parkinson’s disease (PD) [14], it is essential to estimate the cumulative risk of Parkinson’s
disease for LRRK2 mutation carriers for genetic counseling purposes [4, 9]. Ashkenazi Jews (AJ)
are known to have high frequencies of G2019S mutations in LRRK2 gene [19]. The risk for LRRK2
G2019S mutation carriers vary widely in the literature [4]. Moreover, the penetrance estimates
can be modified by genetic or environmental risk factors of age at onset or demographic factors
including ethnic group or gender [5].
To provide precise risk prediction, we estimate the age-specific cumulative risk of Parkinson’s
disease for LRRK2 G2019S carriers and non-carriers in the AJ cohort adjusted for multiple risk
factors. Due to the low frequencies of LRRK2 G2019S mutations in AJ population controls [20],
we studied familial aggregaton of PD using the same validated family history interview at three
academic centers specialized in the care of PD [5, 7, 19]. The family history data on the initial
samples (probands) were collected from the Michael J. Fox Foundation Ashkenazi Jewish LRRK2
Consortium [5, 9, 19]. Although the probands reported on family history of PD, most of the
genotypes of the relatives were not observed [5]. The unobserved genotypes were inferred by the
LRRK2 G2019S mutation status in the probands using the kin-cohort method under a Cox hazards
model to estimate the penetrance of LRRK2 PD in first-degree relatives [5, 9]. The probands were
excluded from the analysis to avoid ascertainment bias [9]. All probands were genotyped for the
LRRK2 G2019S mutation and glucocerebrosidase (GBA) mutations [5, 9]. To investigate the effect
of LRRK2 mutations on PD risk, we excluded probands carrying other known genetic risk factors
such as GBA mutations [5, 9].
The data consists of 2266 first-degree relatives (i.e., 727 parents, 575 siblings, and 964 children)
from 474 families. The participants were recruited at three sites: Beth Israel Medical Center
(n=136), Columbia University Medical Center (n=146), and Tel-Aviv Medical Center (n=192). The
prevalence of LRRK2 G2019S mutation was estimated to be 2% in the AJ population [20]. There
were four groups of mutation probabilities of relatives, pg ∈ {0, 0.02, 0.51, 1} [9], with frequencies
3%, 71%, 22%, and 4%, respectively. Hence, 93% of the first-degree relatives were not genotyped.
Specifically, the percentage of missing genotypes was similar in siblings and children (91%) and
slightly higher in parents (98%). There were 127 relatives with PD (5.6%) and relatives with
censored age-at-onset were excluded from the analysis.
The potential risk factors that may have an impact on the penetrance of PD were considered to
improve the accuracy of the estimation. For example, the recent study by Marder et al. (2015)
showed that relative’s sex may modify the penetrance of LRRK2 G2019S in AJ cohort [5]. In
another study of Ashkenazi PD, the first-degree relatives of female probands with PD were more
likely to have PD compared to that of male probands with PD, even after accounting for LRRK2
G2019S mutations [21]. Moreover, the issue of ascertainment through different academic centers
(site) may have an impact on the penetrance estimates due to the heterogeneity of samples. There-
fore, we aim to estimate the age-specific cumulative risk of PD in LRRK2 mutation carriers and
non-carriers adjusted for relative’s sex and carrier status interaction, proband’s sex, and site of
enrollment in the Ashkenazi Jewish LRRK2 Consortium study. We performed bootstrap based on
families, which accommodates correlation among relatives in the same family. We used exponential
random variables with a mean of one and weighted each family to account for the differential family
data.
We considered using B-splines to estimate β(t) with the number of knots ranging from zero
to three and degrees ranging from one to three. The location of each interior knot was evenly
distributed at the quantiles. No penalty was introduced as the number of knots is small. The
number of knots can be chosen by the Bayesian information criterion (BIC). In the LRRK2 study,
among models with a time-varying β(t), the simplest model with no knots had the smallest BIC (see
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Table S4). Moreover, the model assuming a time-invariant genotype effect β further had a smaller
BIC. Therefore, we fit a final model with a time-invariant hazard for LRRK2 mutation, which
maintains parsimony and facilitates easy interpretation. We also examined the Cox proportional
hazards assumption using the probands data and the assumption was not rejected.
Marginal cumulative risk estimates of PD obtained using (5) based on 1,000 bootstrap resampling
of families are shown in Table S3 along with 95% confidence intervals. After adjusting for relative’s
sex by LRRK2 G2019S mutation interaction, proband’s sex, and recruitment sites, the penetrance
of PD in relatives predicted to carry a G2019S mutation was 24.8% (95% CI: 16.3− 34.3%) to age
80, whereas the cumulative risk for predicted non-carriers was 10.9% (95% CI: 8.1− 14.5%) to age
80. The penetrance estimates were slightly higher for carriers and slightly lower for non-carriers
both by 1% than when unadjusted for the covariates, reported in Marder et al. (2015), but these
changes remained nearly identical.
Figure S5 shows the estimated marginal cumulative risk of PD where the predicted carrier
relatives had a dramatic increase in the risk of developing PD after age 60 as compared to a lower
increase in the predicted non-carrier relatives. While the study unadjusted for the covariates [5]
reported the penetrance of PD in relatives predicted to carry a G2019S mutation was almost 3 fold
higher than non-carrier relatives (HR=2.89; 95% CI: 1.73 − 4.55; p < 0.001), when we examined
the interaction effect between the mutation carrier status and relative’s sex on the risk of PD, the
effect of the carrier status on the risk of PD was significantly modified by gender (HR of interaction
effect θ = 0.3; p = 0.03) such that the effect was reduced for the male relatives (HR=1.47) and
elevated for the female relatives (HR=4.95) (see Table 3). Specifically, when the male and female
relatives were examined separately, the risk of PD for female relatives predicted to have a G2019S
mutation was five-fold higher than non-carrier females (HR=4.95; 95% CI: 2.55− 9.67; p < 0.001)
(Figure 2b), while for male relatives the risk of PD was not significantly increased among male
relatives predicted to carry G2019S mutation compared to non-carrier males (HR=1.47; 95% CI:
0.53− 3.07; p = 0.47) (Figure 2a).
While the penetrance in G2019S carrier relatives and non-carrier relatives differed by gender, the
penetrance to age 80 among predicted mutation carrier male relatives 21.4% (95% CI: 8.9−35.7%),
Table 3: Estimated hazard ratios of Parkinson’s disease onset in the Ashkenazi Jewish LRRK2
Consortium study.
Variable Parameter Est HR Lower limit Upper limit p value
Carrier status in male β + θ 1.47 0.53 3.07 0.472
Carrier status in female β 4.95 2.55 9.67 <0.001
Relative’s sex in carriers η + θ 0.72 0.26 1.56 0.410
Relative’s sex in non-carriers η 2.43 1.50 4.06 <0.001
Carriers · Relative’s sex interaction θ 0.30 0.09 0.86 0.028
Probands’s sex γ1 0.71 0.49 1.02 0.053
Beth Israel vs Columbia γ2 0.78 0.46 1.28 0.328
Tel Aviv vs Columbia γ3 1.18 0.72 1.97 0.483
Beth Israel vs Tel Aviv γ2 − γ3 0.66 0.38 1.11 0.113
The Cox proportional hazards model can be written as
λ(t|Carrier statusXi, Relative′s sexi, P roband′s sexi, Beth Israeli, T el Avivi)
= λ0(t) exp{βXi + ηT I(Relative′s sexi = Male) + θTXiI(Relative′s sexi = Male) + γT1 I(Proband′s sexi = Male)
+γT2 I(Sitei = Beth Israel) + γ
T
3 I(Sitei = Tel Aviv)}.
where Beth Israel and Tel Aviv are dummy variables for three sites with Columbia as reference site.
Denote the estimated hazard ratio (Est HR), 95% confidence interval for the hazard ratio (Lower limit and
Upper limit), and p value.
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was not statistically different from predicted carrier female relatives 28.2% (95% CI: 18.7−40.1%);
HR male to female: 0.72 (95% CI: 0.26−1.56; p = 0.41) (see Table 3 and 4). In contrast, the risk of
PD to age 80 among predicted non-carrier male relatives 15.1% (95% CI: 10.8−20.5%), was higher
than for predicted non-carrier female relatives 6.5% (95% CI: 4.0−10.2%); HR male to female 2.43
(95% CI: 1.50 − 4.06; p < 0.001) was increased by 3% after the adjustment (HR male to female
before the adjustment: 2.40; 95% CI: 1.50 − 4.15; p < 0.001) [5]. The penetrance estimates were
slightly lower for carrier male relatives by 1% and slightly higher for non-carrier male relatives by
0.1% than when unadjusted for the covariates, reported in Marder et al. (2015), but these changes
remained almost identical. Therefore, the large gender difference of penetrance between carrier
relatives and non-carrier relatives is due to the different PD distribution in non-carriers among
Table 4: Estimated cumulative risk of Parkinson’s disease onset in LRRK2 carriers and non-carriers
in male and female relatives marginalized by proband’s sex and site of enrollment in the Ashkenazi
Jewish LRRK2 Consortium study (×10−2).
Carriers F̂1(·) Non-Carriers F̂0(·)
Relative’s sex Age Risk Lower limit Upper limit Risk Lower limit Upper limit
Male 60 6.16 2.31 11.22 4.23 2.55 6.44
65 9.73 3.86 16.80 6.72 4.48 9.70
70 14.32 5.68 24.50 9.98 6.85 14.16
75 17.88 7.07 30.78 12.55 8.93 17.13
80 21.37 8.88 35.67 15.09 10.80 20.50
Female 60 8.41 4.41 13.89 1.77 1.02 2.85
65 13.20 7.64 20.36 2.83 1.64 4.54
70 19.23 12.38 27.82 4.25 2.51 6.65
75 23.82 15.35 34.22 5.39 3.33 8.25
80 28.23 18.66 40.06 6.54 4.00 10.18
Denote the estimated age-specific risk (Risk) and 95% confidence intervals (Lower limit and Upper limit).
(a) Male (b) Female
Figure 2: Estimated age-specific risk of Parkinson’s disease in LRRK2 G2019S carriers (red solid
line) and non-carriers (black solid line) in male and female relatives marginalized by proband’s sex
and site of enrollment with their 95% confidence intervals (dashed lines).
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male and female relatives [5]. These HR are similar to the previous findings where the proband’s
sex and site of enrollment were not controlled additionally [5].
When we specifically examined the effect of proband’s sex and site of enrollment on the pen-
etrance of PD, the risk of PD was not significantly reduced among male probands compared to
female probands (HR=0.71; 95% CI: 0.49−1.02; p = 0.05) and there was no significant heterogene-
ity between sites on the risk of PD, adjusted for other covariates; HR Beth Israel to Columbia=0.78
(95% CI: 0.46 − 1.28; p = 0.33), HR Tel Aviv to Columbia=1.18 (95% CI: 0.72 − 1.97; p = 0.48),
HR Beth Israel to Tel Aviv =0.66 (95% CI: 0.38− 1.11; p = 0.11) (see Table 3). This implies that
proband’s sex and site of enrollment do not play a significant role on the penetrance of PD for the
data collected in the AJ LRRK2 consortium.
To obtain the marginal risk distribution as in Section 2.3 to serve as design parameters, note
that since the mutation status X of the first-degree relatives is independent of covariates W i
collected on the relative (e.g., relative gender) and proband’s covariates Zi (e.g., proband’s sex
and enrollment site), F (W ,Z|X) = F (W ,Z) can be obtained nonparametrically based on the
observed data. When the independence assumption does not hold for other applications, the
conditional distribution of (W ,Z) given X can be estimated by a similar EM algorithm treating
X as missing data. The estimated penetrance for each relative’s sex by carrier status marginalized
by proband’s sex and site of enrollment is reported in Table 4.
To assist with clinical trial planning, we show how to use the estimated penetrance function
to design a disease modifying clinical trial of PD. In a study of Huntington’s disease, sample size
calculations used the length of abnormal expansion of CAG repeat in the HTT gene since the
penetrance is near complete [22]. However, in the PD literatures, using estimated mutation risk
to design a future clinical trial is less common due to the low penetrance for most mutations. The
increased PD risk in LRRK2 carriers compared to non-carriers in the AJ population provides a
unique opportunity to power a future clinical trial in this population.
Assume a study recruits LRRK2 carrier and non-carrier relatives from probands in the three sites
in the AJ consortium. Assume that the PD risk in the placebo arm is the same as observed in our
carrier relatives’ data. We can obtain the placebo arm as the probability of developing PD within
5 years for LRRK2 carrier relatives who are not diagnosed at the baseline as p0 = P (T ≤ t+ 5|T >
t,X = 1) for any given baseline age t using the marginalized estimators provided by our analysis.
Assume the effect of the intervention is to reduce the PD risk in carriers to that as observed in
the non-carrier relatives. Under this assumption, we can estimate the intervention arm as the
proportion of subjects affected by the PD by the end of 5 years as p1 = P (T ≤ t+ 5|T > t,X = 0)
for any given baseline age t. Then the sample size to achieve a power of 80% for testing the
difference between placebo arm and intervention arm, H0 : p0 = p1, can be estimated.
Table 5 summarizes sample size information by baseline age. The results show that when re-
cruiting asymptomatic LRRK2 carriers at age 65, the risk of developing PD within next 5 years
is 6.0% in the control arm. When assuming the intervention reduces the PD risk to the same as
observed in the non-carrier group (scenario 1), the risk of developing PD in the intervention arm,
is 2.5%. To detect a difference of 3.5% (1.1%-5.9%) at 80% power, the required sample size is
n = 521 per arm. The sample size needed for recruiting asymptomatic subjects at other age is also
presented. We also estimated the sample size to achieve a power of 80% for testing a smaller risk
difference between placebo and intervention arm (50% of the previous risk difference); that is, to
test H0 : p0 = p˜1, by letting p˜1 = p0 +(p1−p0)/2. The results in Table 5 show that when recruiting
pre-symptomatic LRRK2 carriers at age 65, the required sample size to detect a difference of 1.7%
at 80% power is n = 2, 492 per arm. A large sample size is required for a prevention trial under
the specified design parameters due to small risk differences.
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Table 5: Sample size estimates for hypothesis testing to achieve 80% power (α = 0.05): Test
difference between placebo arm and intervention arm (Scenario 1), test half of the risk reduction in
scenario 1 (Scenario 2), probability of developing PD within 5 years in placebo arm (p0, assumed to
be the same as observed in carriers), intervention arm of scenario 1 (p1, assumed to be the same as
in non-carriers), intervention arm of scenario 2 (p˜1 that makes half of the risk reduction in scenario
1), difference between two arms (diff), and sample size n per arm.
Scenario 1 Scenario 2
Age p0 p1 diff n per arm p˜1 diff n per arm
60 0.045 0.018 0.027 657 0.032 0.013 3169
65 0.060 0.025 0.035 521 0.042 0.017 2492
70 0.049 0.020 0.029 622 0.034 0.014 2987
75 0.050 0.020 0.030 589 0.035 0.015 2839
80 0.088 0.037 0.051 354 0.062 0.026 1680
The estimated risk in placebo arm and two intervention arms are obtained by
p0 = Pˆ (T ≤ t+ 5|T > t,X = 1) =
[
Fˆ1(t+ 5)− Fˆ1(t)
]
/
[
1− Fˆ1(t)
]
,
p1 = Pˆ (T ≤ t+ 5|T > t,X = 0) =
[
Fˆ0(t+ 5)− Fˆ0(t)
]
/
[
1− Fˆ0(t)
]
,
p˜1 = p0 + (p1 − p0)/2,
where Fˆ1 and Fˆ0 are the estimated marginal cumulative risk functions of PD-onset in LRRK2 carriers and
non-carriers, respectively (see Table S3).
5. Discussion
We propose a sieve maximum likelihood estimation method that permits adjustment for multiple
covariates and interaction effects to estimate disease risk associated with genetic mutation in cen-
sored mixture data. The method allows more precise risk prediction by controlling for individual
characteristics such as sex, ethnicity or other demographics. Moreover, gene-gene interactions and
gene-environment interactions can also be handled within the framework of a single risk model
using our method. These analyses may provide insights into whether these factors play a role
in modifying penetrance. Previous method [9] has been proposed without considering covariates.
Our model and method here permit more precise risk prediction by controlling for covariates that
can further incorporate interaction effects with missing genotypes in relatives. In the application,
when we examined the interaction effect between the mutation carrier status and relative’s sex
on the risk of PD, the effect of the carrier status on the risk of PD was significantly modified
by gender (p = 0.023; Table 3). The proposed method can also be readily generalized to include
time-dependent covariates. For example, PD risk can be associated with clinical or environmental
time-varying covariates. For example, studies have reported that cigaratte smoking is inversely as-
sociated with PD [23]. Therefore, taking into account of duration of smoking or time since quitting
is important in estimating penetrance [24]. Additionally, when the dimension of Zi is high, it may
be of interest to perform variable selection in the M-step of the EM algorithm. Furthermore, we
included effect size calculation to power a clinical trial. The penetrance can be used to design a
prevention trial in order to test an intervention to reduce the risk of PD in asymptomatic LRRK2
p.G2019S mutation carrier relatives in a AJ population. The penetrance estimates can be used
in genetic counseling setting. For example, female Ashkenazi Jewish relatives carrying LRRK2
mutation with female probands recruited at Beth Israel are estimated to have 27.19% cumulative
risk of PD by age 80 in our application.
As an extension of our method, under certain assumptions we can calibrate the genetic risk
prediction model with covariates from samples to the population. Currently, we estimated the
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baseline hazard function from the study sample. However, the sample baseline hazard rate may
not reflect the population baseline hazard rate. Instead, we can estimate the baseline rate in
non-carriers from an external source and include in the model to obtain cumulative risk dis-
tribution in carriers under certain assumptions. When the population prevalence of deleterious
mutation is low, the baseline cumulative hazard of a disease is readily available from national-
based surveys or administrative databases. Assuming the hazard ratios for (Xi,W i,Zi) are the
same between the study sample and the underlying population, the model for the study sample
is λs(t|Xi,W i,Zi) = λ0s(t) exp{β(t)Xi + ηTW i + θTW iZi + γTZi}, and for the population is
λ˜(t|Xi,W i,Zi) = λ˜0(t) exp{β(t)Xi + ηTW i + θTW iXi + γTZi}, where the difference between
two models is the baseline hazard function. Combining the baseline cumulative hazard function
obtained from external resource with regression coefficients estimated from the study sample, the
genetic risk function for the carrier group can be obtained under specified assumptions. Such esti-
mation can be performed when planning clinical trials on certain populations with known baseline
cumulative risk of disease.
In the studies we considered here, relatives’ disease onset phenotypes were collected cross-
sectionally from examining probands in each family. Probands’ ascertainment is through a disease
consortium and primarily clinic-based. Thus, relatives’ missing genotypes due to death and cen-
soring is unlikely to be directly associated with their disease onset ages given that a proband is
recruited. In other words, relatives’ missing genotypes or censoring can be conditionally indepen-
dent of their PD onset given proband’s ascertainment scheme and covariates, and hence properly
accounted for. One source of bias may be length-biased sampling (for example, probands who
are younger and with longer duration of PD may be more likely to be recruited), and alternative
methods [25] can be considered in this case. Our method can be modified in the presence of com-
peting risks to account for cause-specific hazards along the lines of [26]. Unfortunately, a limitation
of LRRK2 study is that the cause of death in deceased relatives was not available. Lastly, due
to a small number of GBA carriers in the LRRK2 study sample, estimation of LRRK2 by GBA
interaction was not stable and thus not reported.
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Appendix A. Additional simulation results
Based on the simulation results from 1,000 replications with 1,000 bootstrap samples in Section 3 and using
model (5), we estimated the marginal cumulative risk functions in carriers and non-carriers in Figure S1 and the
performance of the estimates at various ages with censoring rate of 40% or 60% in Table S1. The penetrance
estimates in male and female relatives were examined separately along with their 95% confidence intervals with
the censoring rate of 40% and 60% in Figure 1 and Figure S2, respectively. Moreover, Figure S3 and S4 presents
the penetrance estimates in male and female relatives of male and female probands and Table S2 shows the
performance of the estimates at various ages with the censoring rate of 40% or 60%.
In Table 2, S1, and S2, we observed the small bias of estimated penetrance over the entire range of age and the
estimated standard errors agrees adequately with the empirical standard deviations, and the coverage probabilities
were close to the nominal level.
Table S1: Summary results for the marginal penetrance estimates marginalized by relative’s sex
and proband’s sex in the simulation (×10−2) with censoring rate of 40% or 60%.
Carrier F̂1(·) Non-Carrier F̂0(·)
Censor Age True Risk Bias SD SE CP True Risk Bias SD SE CP
40% 60 19.00 0.16 1.69 1.71 94.4 7.97 <0.01 0.56 0.56 95.3
65 26.91 0.21 2.13 2.13 94.0 11.61 <0.01 0.70 0.69 94.6
70 36.38 0.24 2.56 2.56 94.4 16.29 <0.01 0.83 0.82 95.1
75 47.02 0.24 2.91 2.90 94.5 22.06 <0.01 0.97 0.95 94.3
80 58.16 0.25 3.19 3.11 94.1 28.88 0.04 1.04 1.06 96.1
60% 60 19.00 -0.43 1.81 1.87 94.8 7.97 0.10 0.59 0.58 94.4
65 26.91 -0.60 2.32 2.38 94.4 11.61 0.14 0.72 0.72 95.6
70 36.38 -0.73 2.80 2.90 95.3 16.29 0.21 0.89 0.86 94.2
75 47.02 -1.05 3.20 3.37 95.7 22.06 0.17 1.01 1.01 94.5
80 58.16 -1.55 3.56 3.70 94.2 28.88 -0.03 1.19 1.16 93.9
Denote the true cumulative risk (True Risk), average estimation bias over 1,000 replications (Bias),
empirical standard deviation (SD), average of estimated standard errors from bootstraps (SE), and
coverage probability corresponding to nominal 95% confidence intervals (CP). Results are based on 1,000
simulations with sample size n = 2266.
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(a) 40% censoring rate (b) 60% censoring rate
Figure S1: Estimated marginal cumulative risk functions in the simulation with censoring rate of
40% or 60%: Carriers (red solid line) and non-carriers (black solid line) with their 95% confidence
intervals (dashed lines) and true cumulative risk functions (blue solid line).
(a) Male relatives (b) Female relatives
Figure S2: Estimated cumulative risk functions in the simulation with 60% censoring rate: Carriers
(red solid line) and non-carriers (black solid line) in male and female relatives marginalized by
probands’ sex with their 95% confidence intervals (dashed lines) and true cumulative risk functions
(blue solid line).
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Table S2: Summary results for the penetrance estimates in male and female relatives of male and
female probands in the simulation (×10−2) with censoring rate of 40% or 60%.
Carrier F̂1(·) Non-Carrier F̂0(·)
Censor Rel sex Prob sex Age True Risk Bias SD SE CP True Risk Bias SD SE CP
40% Male Male 60 14.20 0.02 1.77 1.77 94.8 9.56 0.06 0.76 0.75 94.8
65 20.43 0.04 2.38 2.35 94.5 13.92 0.10 0.96 0.95 94.1
70 28.18 0.04 3.03 2.99 93.7 19.52 0.14 1.19 1.16 94.9
75 37.33 0.03 3.68 3.62 94.0 26.41 0.18 1.44 1.39 93.6
80 47.55 0.06 4.25 4.14 93.5 34.52 0.27 1.62 1.60 94.9
Female 60 19.49 -0.04 2.36 2.36 94.3 13.26 0.04 1.01 1.03 94.6
65 27.63 -0.04 3.06 3.05 94.4 19.12 0.07 1.26 1.27 95.3
70 37.40 -0.08 3.73 3.73 94.7 26.47 0.10 1.49 1.53 95.7
75 48.39 -0.13 4.30 4.27 94.3 35.21 0.12 1.75 1.78 95.9
80 59.88 -0.13 4.63 4.55 93.7 45.08 0.20 1.90 1.97 96.1
Female Male 60 18.94 0.32 2.34 2.32 94.2 4.12 -0.05 0.39 0.39 93.9
65 26.90 0.44 3.06 3.01 94.1 6.08 -0.06 0.53 0.52 94.2
70 36.48 0.53 3.80 3.71 93.9 8.69 -0.09 0.70 0.68 92.7
75 47.31 0.58 4.40 4.30 94.5 12.04 -0.12 0.90 0.87 93.5
80 58.72 0.63 4.82 4.65 93.6 16.24 -0.13 1.10 1.09 94.1
Female 60 25.71 0.33 3.07 3.03 93.9 5.78 -0.08 0.53 0.52 94.0
65 35.82 0.42 3.84 3.78 93.9 8.50 -0.11 0.71 0.69 93.1
70 47.39 0.46 4.48 4.40 94.2 12.07 -0.16 0.92 0.90 93.5
75 59.62 0.42 4.81 4.73 94.3 16.61 -0.21 1.17 1.14 93.5
80 71.42 0.38 4.78 4.63 94.1 22.18 -0.24 1.41 1.40 93.8
60% Male Male 60 14.20 -0.08 2.02 1.97 93.7 9.56 0.17 0.81 0.81 94.7
65 20.43 -0.14 2.71 2.64 93.5 13.92 0.24 1.04 1.03 94.9
70 28.18 -0.17 3.46 3.39 94.3 19.52 0.35 1.32 1.29 93.7
75 37.33 -0.39 4.16 4.13 95.0 26.41 0.33 1.57 1.56 94.2
80 47.55 -0.83 4.81 4.77 94.3 34.52 0.13 1.88 1.84 94.7
Female 60 19.49 -0.22 2.61 2.64 94.3 13.26 0.17 1.08 1.11 95.1
65 27.63 -0.33 3.41 3.43 94.5 19.12 0.22 1.37 1.39 95.2
70 37.40 -0.40 4.18 4.23 94.8 26.47 0.33 1.71 1.70 95.1
75 48.39 -0.69 4.77 4.90 95.2 35.21 0.26 1.98 2.02 95.1
80 59.88 -1.19 5.17 5.30 95.1 45.08 -0.03 2.33 2.32 94.6
Female Male 60 18.94 -0.60 2.56 2.60 93.8 4.12 0.04 0.45 0.45 95.0
65 26.90 -0.83 3.38 3.42 94.3 6.08 0.05 0.61 0.61 95.1
70 36.48 -1.04 4.22 4.28 94.3 8.69 0.08 0.82 0.81 95.5
75 47.31 -1.44 4.96 5.03 94.0 12.04 0.05 1.04 1.05 95.7
80 58.72 -2.01 5.50 5.55 94.0 16.24 -0.08 1.30 1.31 96.1
Female 60 25.71 -0.90 3.32 3.42 94.3 5.78 0.02 0.60 0.60 94.2
65 35.82 -1.22 4.22 4.32 93.9 8.50 0.03 0.82 0.81 93.8
70 47.39 -1.46 5.00 5.12 94.0 12.07 0.05 1.08 1.07 94.1
75 59.62 -1.86 5.49 5.62 93.8 16.61 -0.01 1.37 1.37 94.5
80 71.42 -2.32 5.58 5.68 93.8 22.18 -0.21 1.70 1.69 94.1
Denote the true cumulative risk (True Risk), average estimation bias over 1,000 replications (Bias),
empirical standard deviation (SD), average of estimated standard errors from bootstraps (SE), and
coverage probability corresponding to nominal 95% confidence intervals (CP). Results are based on 1,000
simulations with sample size n = 2266.
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(a) Male relatives of male proband (b) Male relatives of female proband
(c) Female relatives of male proband (d) Female relatives of female proband
Figure S3: Estimated cumulative risk functions in the simulation with 40% censoring rate: Carriers
(red solid line) and non-carriers (black solid line) in male and female relatives of male and female
probands with their 95% confidence intervals (dashed lines) and true cumulative risk functions
(blue solid line).
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(a) Male relatives of male proband (b) Male relatives of female proband
(c) Female relatives of male proband (d) Female relatives of female proband
Figure S4: Estimated cumulative risk functions in the simulation with 60% censoring rate: Carriers
(red solid line) and non-carriers (black solid line) in male and female relatives of male and female
probands with their 95% confidence intervals (dashed lines) and true cumulative risk functions
(blue solid line).
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Appendix B. Additional data analyses results
Based on the parameter estimates that we obtained in the Ashkenazi Jewish LRRK2 Consortium study in Section
4, the marginal cumulative risk functions in LRRK2 G2019S carriers and non-carriers can be estimated using model
(5) and the results are in Table S3 and Figure S5. We adjusted for relative’s sex and carrier status interaction,
proband’s sex, and site of enrollment to provide precise risk prediction and we compared the penetrance estimates
to the one in Marder et al. (2015) where none of the covariates were controlled.
Table S3: Estimated marginal cumulative risk of Parkinson’s disease onset in LRRK2 carriers and
non-carriers in the Ashkenazi Jewish LRRK2 Consortium study (×10−2).
Carrier F̂1(·) Non-Carrier F̂0(·)
Age Risk Lower limit Upper limit Risk Lower limit Upper limit
Adjusted (Proposed) 60 7.27 4.18 11.16 3.01 1.94 4.45
65 11.44 6.86 16.50 4.80 3.28 6.83
70 16.74 10.84 23.46 7.15 4.93 9.88
75 20.81 13.27 28.86 9.01 6.68 11.99
80 24.75 16.26 34.26 10.87 8.07 14.46
Unadjusted (Marder et al., 2015) 60 7.84 4.61 12.27 2.79 1.80 3.99
65 12.28 7.59 17.89 4.44 3.11 6.08
70 17.89 12.05 24.83 6.60 4.70 8.95
75 22.16 15.03 30.39 8.31 6.13 10.99
80 26.22 17.94 36.30 10.00 7.31 13.37
The penetrance estimates adjusted for relative’s sex and carrier status interaction, proband’s sex, and site
of enrollment (Proposed) was compared to the penetrance estimates unadjusted for any covariates reported
in the previous study (Marder et al., 2015). Denote the estimated age-specific risk (Risk) and 95%
confidence intervals (Lower limit and Upper limit).
Table S4: BIC for analyses assuming time-invariant genotype effect β (Cox PH model) and time-
varying genotype effect β(t) estimated by B-splines with various number of knots and degrees in
the Ashkenazi Jewish LRRK2 Consortium study.
Analysis∗ Cox PH model Time-varying genotype effect
Number of knots
degree 0 1 2 3
Scenario 1 91.6 Linear 105.9 111.5 119.6 125.3
Quadratic 108.8 120.4 126.8 135.8
Cubic 120.4 129.0 137.6 144.3
Scenario 2 97.0 Linear 111.6 116.8 125.1 130.5
Quadratic 114.0 126.0 127.6 139.8
Cubic 126.0 134.8 143.3 151.5
Scenario 3 114.6 Linear 129.4 134.7 143.0 148.3
Quadratic 131.9 143.9 145.5 157.5
Cubic 143.8 152.7 161.2 169.2
∗: Scenario 1 adjusted for relative’s sex and carrier status interaction. Scenario 2 adjusted for relative’s sex
and carrier status interaction and proband’s sex. Scenario 3 adjusted for relative’s sex and carrier status
interaction, proband’s sex, and site of enrollment.
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Figure S5: Estimated marginal age-specific risk of Parkinson’s disease (PD) in LRRK2 G2019S
carriers (red solid line) and non-carriers (black solid line) with their 95% confidence intervals (dashed
lines).
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